Journal
MOLECULAR PHARMACEUTICS
Volume 10, Issue 1, Pages 3-10Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp3002057
Keywords
Cowpea mosaic virus; doxorubicin; drug delivery; viral nanoparticle; cancer
Funding
- NIH/NIBIB [R00 EB009105, P30 EB011317]
- Biotechnology and Biological Sciences Research Council, U.K.
- BBSRC [BBS/E/J/000C0648] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BBS/E/J/000C0648] Funding Source: researchfish
Ask authors/readers for more resources
The plant virus, Cowpea mosaic virus (CPMV), is developed as a carrier of the chemotherapeutic drug doxorubicin (DOX). CPMV-DOX conjugate, in which eighty DOX molecules are covalently bound to external surface carboxylates of the viral nanoparticle (VNP), shows greater cytotoxicity than free DOX toward HeLa cells when administered at low dosage. At higher concentrations, CPMV-DOX cytotoxicity is time-delayed. The CPMV conjugate is targeted to the endolysosomal compartment of the cells, in which the proteinaceous drug carrier is degraded and the drug released. This study is the first demonstrating the utility of CPMV as a drug delivery vehicle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
